You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTenoxicam
Accession NumberDB00469  (APRD00011)
TypeSmall Molecule
GroupsApproved
DescriptionTenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Structure
Thumb
Synonyms
Tenoxicam
Ténoxicam
Tenoxicamum
External Identifiers
  • RO 12-0068
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mobiflex Tab 20mgTablet20 mgOralHoffmann La Roche Limited1991-12-312001-07-19Canada
Novo-tenoxicam Tab 20mgTablet20 mgOralNovopharm Limited1997-06-052005-08-10Canada
Nu-tenoxicamTablet20 mgOralNu Pharm IncNot applicableNot applicableCanada
Tenoxicam TabletsTablet20 mgOralAa Pharma Inc1997-02-21Not applicableCanada
Tenoxicam-20Tablet20 mgOralPro Doc Limitee1998-11-242009-07-23Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MobiflexRoche
OctiveranRafarm
OxicamACI
OxytelCoup
PalitenoxPharmathen
TenorixOrion
TenxilUnison
TilcotilMeda
TilflamDexa Medica
TilkoKoçak
TilnoxcamT. O. Chemicals
TiloxicanHexal
TobitilRanbaxy
TonoxUtopian
ToscacalmGenepharm
VelasorVocate
VienoksToprak
VoirVelka
XicotilAristopharma
ZibelantChrispa
ZikaralSanovel
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIZ1R9N0A399
CAS number59804-37-4
WeightAverage: 337.37
Monoisotopic: 337.019098194
Chemical FormulaC13H11N3O4S2
InChI KeyLZNWYQJJBLGYLT-UHFFFAOYSA-N
InChI
InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
IUPAC Name
4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶-thieno[2,3-e][1,2]thiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
Pharmacology
IndicationFor the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.
Structured Indications
PharmacodynamicsTenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Mechanism of actionThe antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionOral absorption of tenoxicam is rapid and complete (absolute bioavailability 100%).
Volume of distributionNot Available
Protein binding99%
Metabolism

Tenoxicam is metabolized in the liver to several pharmacologically inactive metabolites (mainly 5'-hydroxy-tenoxicam).

SubstrateEnzymesProduct
Tenoxicam
5'-HydroxytenoxicamDetails
Route of eliminationNot Available
Half life72 hours (range 59 to 74 hours)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tenoxicam Action PathwayDrug actionSMP00706
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabTenoxicam may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Tenoxicam can be decreased when combined with Abiraterone.Approved
AcebutololTenoxicam may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Aceclofenac.Approved
AcenocoumarolTenoxicam may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinTenoxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tenoxicam.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid.Approved
AliskirenTenoxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololTenoxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tenoxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Amcinonide.Approved
AmikacinTenoxicam may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTenoxicam may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Tenoxicam can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinTenoxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTenoxicam may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Anisodamine.Investigational
annamycinTenoxicam may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Antipyrine.Approved
Antithrombin III humanTenoxicam may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Tenoxicam may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanTenoxicam may increase the anticoagulant activities of Apixaban.Approved
ApramycinTenoxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Tenoxicam can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinTenoxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinTenoxicam may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanTenoxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTenoxicam may decrease the antihypertensive activities of Arotinolol.Approved
AtenololTenoxicam may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tenoxicam.Approved
BalsalazideTenoxicam may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminTenoxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTenoxicam may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tenoxicam.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tenoxicam.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tenoxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololTenoxicam may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Betulinic Acid.Investigational
BevantololTenoxicam may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tenoxicam.Approved, Investigational
BisoprololTenoxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTenoxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTenoxicam may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Bucillamine.Investigational
BucindololTenoxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Budesonide.Approved
BufuralolTenoxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideTenoxicam may decrease the diuretic activities of Bumetanide.Approved
BupranololTenoxicam may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tenoxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tenoxicam.Experimental
CapecitabineThe metabolism of Tenoxicam can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tenoxicam.Approved
CarbamazepineThe metabolism of Tenoxicam can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tenoxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTenoxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTenoxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Celecoxib.Approved, Investigational
CeliprololTenoxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Tenoxicam can be increased when it is combined with Ceritinib.Approved
CertoparinTenoxicam may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenoxicam.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tenoxicam.Approved
CholecalciferolThe metabolism of Tenoxicam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tenoxicam.Approved
CinoxacinTenoxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinTenoxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidTenoxicam may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tenoxicam.Vet Approved
ClotrimazoleThe metabolism of Tenoxicam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Curcumin.Investigational
CyclosporineTenoxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Tenoxicam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with D-Limonene.Investigational
Dabigatran etexilateTenoxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Tenoxicam can be decreased when it is combined with Dabrafenib.Approved
DalteparinTenoxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTenoxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinTenoxicam may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Tenoxicam can be decreased when combined with Delavirdine.Approved
DesirudinTenoxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tenoxicam.Approved
DextranTenoxicam may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Tenoxicam may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tenoxicam may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tenoxicam may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tenoxicam.Approved, Vet Approved
DicoumarolTenoxicam may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tenoxicam.Approved
DihydrostreptomycinTenoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tenoxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tenoxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tenoxicam.Approved
DoxorubicinTenoxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTenoxicam may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Tenoxicam is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ebselen.Investigational
Edetic AcidTenoxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTenoxicam may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Tenoxicam can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tenoxicam.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tenoxicam.Approved
EnoxacinTenoxicam may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinTenoxicam may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Epirizole.Approved
EpirubicinTenoxicam may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTenoxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tenoxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tenoxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Equilin.Approved
EsmololTenoxicam may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Estrone sulfate.Approved
Etacrynic acidTenoxicam may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tenoxicam.Approved, Investigational
Ethyl biscoumacetateTenoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Tenoxicam can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Tenoxicam is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tenoxicam.Vet Approved
FleroxacinTenoxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tenoxicam.Approved, Withdrawn
FloxuridineThe metabolism of Tenoxicam can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with fluasterone.Investigational
FluconazoleThe metabolism of Tenoxicam can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fludrocortisone.Approved
FluindioneTenoxicam may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTenoxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Tenoxicam can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tenoxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Tenoxicam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Tenoxicam can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tenoxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxTenoxicam may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTenoxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tenoxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tenoxicam.Approved
FosphenytoinThe metabolism of Tenoxicam can be increased when combined with Fosphenytoin.Approved
FramycetinTenoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideTenoxicam may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateTenoxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTenoxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTenoxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tenoxicam.Approved, Withdrawn
GemfibrozilThe metabolism of Tenoxicam can be decreased when combined with Gemfibrozil.Approved
GemifloxacinTenoxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTenoxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTenoxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATenoxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinTenoxicam may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Tenoxicam is combined with HE3286.Investigational
HeparinTenoxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Higenamine.Investigational
HirulogTenoxicam may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Tenoxicam is combined with HMPL-004.Investigational
HydralazineTenoxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tenoxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tenoxicam.Approved
Hygromycin BTenoxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Icatibant.Approved
IdarubicinTenoxicam may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxTenoxicam may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tenoxicam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tenoxicam.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tenoxicam.Approved
IndenololTenoxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Tenoxicam can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenoxicam.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Indoprofen.Withdrawn
INNO-206Tenoxicam may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Tenoxicam can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Istaroxime.Investigational
KanamycinTenoxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Tenoxicam can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tenoxicam.Approved
LabetalolTenoxicam may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tenoxicam.Approved, Investigational
LeflunomideThe metabolism of Tenoxicam can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinTenoxicam may increase the anticoagulant activities of Lepirudin.Approved
LevobunololTenoxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTenoxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tenoxicam.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tenoxicam.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tenoxicam.Approved
LomefloxacinTenoxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lornoxicam.Approved
LosartanThe metabolism of Tenoxicam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Tenoxicam can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tenoxicam.Approved, Investigational
LumacaftorThe serum concentration of Tenoxicam can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tenoxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tenoxicam.Approved
ME-609The risk or severity of adverse effects can be increased when Tenoxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mefenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meloxicam.Approved, Vet Approved
MesalazineTenoxicam may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tenoxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenoxicam.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTenoxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tenoxicam.Approved
MetoprololTenoxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTenoxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Tenoxicam can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tenoxicam.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tenoxicam.Approved
MometasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tenoxicam.Approved
MoxifloxacinTenoxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nabumetone.Approved
NadololTenoxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTenoxicam may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTenoxicam may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Naftifine.Approved
Nalidixic AcidTenoxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Tenoxicam is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Tenoxicam is combined with NCX 4016.Investigational
NeamineTenoxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinTenoxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTenoxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nepafenac.Approved
NetilmicinTenoxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Tenoxicam can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nitroaspirin.Investigational
NorfloxacinTenoxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinTenoxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tenoxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Olopatadine.Approved
OlsalazineTenoxicam may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tenoxicam.Investigational
OmeprazoleThe metabolism of Tenoxicam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Orgotein.Vet Approved
OtamixabanTenoxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxaprozin.Approved
OxprenololTenoxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Parecoxib.Approved
ParomomycinTenoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinTenoxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTenoxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTenoxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateTenoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tenoxicam.Approved
PhenindioneTenoxicam may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Tenoxicam can be increased when combined with Phenobarbital.Approved
PhenprocoumonTenoxicam may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Tenoxicam can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenoxicam.Approved, Investigational
PindololTenoxicam may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinTenoxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTenoxicam may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Piroxicam.Approved, Investigational
PlicamycinTenoxicam may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tenoxicam.Approved
PractololTenoxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tenoxicam.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Tenoxicam can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Tenoxicam can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Propacetamol.Approved
PropranololTenoxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tenoxicam.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Tenoxicam.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tenoxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tenoxicam.Vet Approved
Protein CTenoxicam may increase the anticoagulant activities of Protein C.Approved
ProtocatechualdehydeTenoxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTenoxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Tenoxicam is combined with PTC299.Investigational
PuromycinTenoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Tenoxicam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tenoxicam.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tenoxicam.Approved
QuinineThe metabolism of Tenoxicam can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tenoxicam.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tenoxicam.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Resveratrol.Experimental, Investigational
ReviparinTenoxicam may increase the anticoagulant activities of Reviparin.Approved
RibostamycinTenoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Tenoxicam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Tenoxicam can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Risedronate.Approved, Investigational
RivaroxabanTenoxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinTenoxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tenoxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tenoxicam.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tenoxicam.Investigational
SecobarbitalThe metabolism of Tenoxicam can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Seratrodast.Approved, Investigational
SildenafilThe metabolism of Tenoxicam can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinTenoxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Tenoxicam can be decreased when combined with Sorafenib.Approved, Investigational
SotalolTenoxicam may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTenoxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTenoxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinTenoxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tenoxicam.Approved
SpironolactoneTenoxicam may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Tenoxicam is combined with SRT501.Investigational
StreptomycinTenoxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTenoxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Tenoxicam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Tenoxicam can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineTenoxicam may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Tenoxicam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Sulindac.Approved
SulodexideTenoxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tenoxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Suprofen.Approved, Withdrawn
TacrolimusTenoxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tenoxicam.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tenoxicam.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tenoxicam.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tenoxicam.Approved, Investigational
TemafloxacinTenoxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tenoxicam.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tenofovir.Approved, Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Tenoxicam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Tenoxicam can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tiludronate.Approved, Vet Approved
TimololTenoxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tixocortol.Approved
TobramycinTenoxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Tenoxicam can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolmetin.Approved
TorasemideTenoxicam may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tenoxicam.Approved
TranilastThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tenoxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tenoxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTenoxicam may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tenoxicam.Approved, Vet Approved
TrimethoprimThe metabolism of Tenoxicam can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Trisalicylate-choline.Approved
TrovafloxacinTenoxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tenoxicam.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Tenoxicam can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinTenoxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Tenoxicam can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tenoxicam.Approved
VoriconazoleThe metabolism of Tenoxicam can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinTenoxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTenoxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Tenoxicam may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Tenoxicam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zileuton.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zomepirac.Withdrawn
ZorubicinTenoxicam may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AC02
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier-0.9455
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5536
P-glycoprotein inhibitor INon-inhibitor0.7976
P-glycoprotein inhibitor IINon-inhibitor0.8024
Renal organic cation transporterNon-inhibitor0.9191
CYP450 2C9 substrateSubstrate0.6922
CYP450 2D6 substrateNon-substrate0.8896
CYP450 3A4 substrateNon-substrate0.7105
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.7661
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8966
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9057
Ames testNon AMES toxic0.8655
CarcinogenicityNon-carcinogens0.7271
BiodegradationNot ready biodegradable0.936
Rat acute toxicity3.4010 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9633
hERG inhibition (predictor II)Non-inhibitor0.8785
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral20 mg
Prices
Unit descriptionCostUnit
Apo-Tenoxicam 20 mg Tablet1.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point211 dec °CPhysProp
water solubility14.1 mg/LNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.257 mg/mLALOGPS
logP2.42ALOGPS
logP-0.12ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)2.21ChemAxon
pKa (Strongest Basic)4.26ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity83.93 m3·mol-1ChemAxon
Polarizability31.96 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Substituents
  • Alpha-amino acid or derivatives
  • Thienothiazine
  • N-arylamide
  • Ortho-thiazine
  • Pyridine
  • Imidolactam
  • Organosulfonic acid amide
  • Heteroaromatic compound
  • Organic sulfonic acid or derivatives
  • Organosulfonic acid or derivatives
  • Vinylogous acid
  • Thiophene
  • Carboxamide group
  • Secondary carboxylic acid amide
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organooxygen compound
  • Organonitrogen compound
  • Organopnictogen compound
  • Carbonyl group
  • Organic nitrogen compound
  • Organic oxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J: Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study. Indian J Biochem Biophys. 2001 Feb-Apr;38(1-2):56-63. [PubMed:11563332 ]
  2. Yamada M, Niki H, Yamashita M, Mue S, Ohuchi K: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J Pharmacol Exp Ther. 1997 May;281(2):1005-12. [PubMed:9152412 ]
  3. Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H: In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci. 2005 Spring;35(2):137-43. [PubMed:15943176 ]
  4. Yilmaz H, Gurel S, Ozdemir O: The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42. [PubMed:16245223 ]
  5. Galvao RI, Diogenes JP, Maia GC, Filho EA, Vasconcelos SM, de Menezes DB, Cunha GM, Viana GS: Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res. 2005 Jan;30(1):39-46. [PubMed:15756931 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Yamada M, Niki H, Yamashita M, Mue S, Ohuchi K: Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J Pharmacol Exp Ther. 1997 May;281(2):1005-12. [PubMed:9152412 ]
  2. Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H: In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci. 2005 Spring;35(2):137-43. [PubMed:15943176 ]
  3. Lucio M, Ferreira H, Lima JL, Reis S: Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity. Med Chem. 2006 Sep;2(5):447-56. [PubMed:17017983 ]
  4. Lora M, Morisset S, Menard HA, Leduc R, de Brum-Fernandes AJ: Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids. 1997 May;56(5):361-7. [PubMed:9175172 ]
  5. Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J: Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study. Indian J Biochem Biophys. 2001 Feb-Apr;38(1-2):56-63. [PubMed:11563332 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23